SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Lost Money on XBiotech Inc. (XBIT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
XBiotech Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - XBIT
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shareholders that Lost Money on XBiotech Inc. (XBIT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - XBIT
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
An Investigation Has Commenced on Behalf of XBiotech Inc. Shareholders. Contact Levi & Korsinsky to Discuss your XBIT Losses.
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
XBIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by XBiotech Inc.
NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - XBIT
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
